

**APPENDIX E**

<b>Claim Text</b>	<b>Origin</b>
<p><b>56. [A combination of Claims 5 and 34 (including the limitations of the claim(s) from which they depend) of the '531 application</b></p> <p>A vaccine which protects a pig against a porcine reproductive and respiratory syndrome (PRRS), comprising an inactivated or attenuated virus wherein prior to inactivation or attenuation, said virus is</p> <p>selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431), and ISU-1894 (VR 2475), and</p> <p>a physiologically-acceptable carrier, wherein said inactivated or attenuated virus is prepared by serial passage</p> <p>in a cell line selected from the group consisting of PSP-36, PSP-36-SAH, and MA-104.</p>	<p><b><u>Claim 34</u></b> A vaccine which protects a pig against porcine reproductive and respiratory syndrome (PRRS) comprising an inactivated or attenuated virus wherein prior to inactivation or attenuation, said virus is</p> <p><b><u>Claim 31</u></b> . . . selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431) and ISU-1894.</p> <p><b><u>Claim 34</u></b> . . . prepared by serial passage in cell culture and a physiologically acceptable carrier . . .</p> <p><b><u>Claim 5</u></b> The vaccine of Claim 1, wherein said vaccine is prepared from a virus cultured in a cell line selected from the group consisting of PSP-36, PSP-36-SAH and MA-104.</p>